BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) reported today that researchers at the University of Texas Southwestern Medical Center (UTSW) in Dallas, Texas, published a new paper elaborating on the regenerative effects of Tß4 on heart cells and blood vessel growth after a heart attack in a rodent model. According to UTSW, “The new findings in mice suggest that introducing Tß4 systemically after a heart attack encourages new growth and repair of heart cells. The research findings indicate that the molecule affects developmental gene expression as early as 24 hours after systemic injection.” The researchers also state that, “Tß4 is the first known molecule capable of organ-wide activation of embryonic coronary developmental program in the adult mammalian heart after systemic administration...”
